Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Fleur Laponder

Fleur Laponder
Efficacy of Imatinib in ABL-class fusion positive ALL

Fleur Laponder studies Life Science at the University of Applied Sciences Utrecht. She started working as an intern in the Den Boer group September 2021 focusing on a project involving ABL-class B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

In about 3% of children with newly diagnosed ALL, new ABL-class fusions other than BCR-ABL1 have been detected. Similar to BCR-ABL1 positive leukemia, these new ABL-class cases are reported to be sensitive to tyrosine kinase inhibitors (TKI) in case-report studies. However, many different fusion partners exists and till date it is unclear whether these are all equally sensitive to different types of TKIs. To understand whether the drug sensitivity is dependent on the type of fusion, transduced cell line models harboring ABL class fusions will be generated and exposed to different TKIs. The data of these cell line models will be compared to ex vivo drug sensitivity data of ABL class patients harboring the same lesions. Hopefully, by understanding for which TKIs the different ABL class lesions are sensitive and the mechanisms of resistance, patients may be treated differently in future based on their specific ABL class fusion and/or resistant response to specific TKIs.